Ερευνητικό υλικό ΕΚΠΑ

COVID-19 severity and mortality in patients with CLL: an update of the
international ERIC and Campus CLL study

Αγγλικά

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible
to Coronavirus disease 2019 (COVID-19) due to age, disease, and
treatment-related immunosuppression. We aimed to assess risk factors of
outcome and elucidate the impact of CLL-directed treatments on the
course of COVID-19. We conducted a retrospective, international study,
collectively including 941 patients with CLL and confirmed COVID-19.
Data from the beginning of the pandemic until March 16, 2021, were
collected from 91 centers. The risk factors of case fatality rate (CFR),
disease severity, and overall survival (OS) were investigated. OS
analysis was restricted to patients with severe COVID-19 (definition:
hospitalization with need of oxygen or admission into an intensive care
unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior
for patients in all treatment categories compared to untreated (p <
0.001). Untreated patients had a lower risk of death (HR = 0.54, 95%
CI:0.41-0.72). The risk of death was higher for older patients and those
suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79,
95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and
cardiac failure were significant risk factors of OS. Untreated patients
had a better chance of survival than those on treatment or recently
treated.

2021

Chatzikonstantinou, Thomas
Kapetanakis, Anargyros
Scarfo, Lydia
and Karakatsoulis, Georgios
Allsup, David
Alonso Cabrero,
Alejandro
Andres, Martin
Antic, Darko
Baile, Monica and
Baliakas, Panagiotis
Bron, Dominique
Capasso, Antonella and
Chatzileontiadou, Sofia
Cordoba, Raul
Correa, Juan-Gonzalo and
Cuellar-Garcia, Carolina
De Paoli, Lorenzo
De Paolis, Maria
Rosaria
Del Poeta, Giovanni
Demosthenous, Christos
Dimou,
Maria
Donaldson, David
Doubek, Michael
Efstathopoulou, Maria
and Eichhorst, Barbara
El-Ashwah, Shaimaa
Enrico, Alicia and
Espinet, Blanca
Farina, Lucia
Ferrari, Angela
Foglietta,
Myriam
Frederiksen, Henrik
Furstenau, Moritz
Garcia-Marco,
Jose A.
Garcia-Serra, Rocio
Gentile, Massimo
Gimeno, Eva and
Glenthoj, Andreas
da Silva, Maria Gomes
Gutwein, Odit and
Hakobyan, Yervand K.
Herishanu, Yair
Angel Hernandez-Rivas, Jose
and Herold, Tobias
Innocenti, Idanna
Itchaki, Gilad
Jaksic,
Ozren
Janssens, Ann
Kalashnikova, Olga B.
Kalicinska,
Elzbieta
Karlsson, Linda Katharina
Kater, Arnon P.
Kersting,
Sabina
Labrador, Jorge
Lad, Deepesh
Laurenti, Luca and
Levin, Mark-David
Lista, Enrico
Lopez-Garcia, Alberto and
Malerba, Lara
Marasca, Roberto
Marchetti, Monia
Marquet,
Juan
Mattsson, Mattias
Mauro, Francesca R.
Milosevic, Ivana
and Miras, Fatima
Morawska, Marta
Motta, Marina
Munir, Talha
and Murru, Roberta
Niemann, Carsten U.
Rodrigues, Raquel Nunes
and Olivieri, Jacopo
Orsucci, Lorella
Papaioannou, Maria and
Arturo Pavlovsky, Miguel
Piskunova, Inga
Popov, Viola Maria and
Quaglia, Francesca Maria
Quaresmini, Giulia
Qvist, Kristian and
Reda, Gianluigi
Rigolin, Gian Matteo
Ruchlemer, Rosa and
Saghumyan, Gevorg
Shrestha, Amit
Simkovic, Martin
Spacek,
Martin
Sportoletti, Paolo
Stanca, Oana
Stavroyianni, Niki
and Tadmor, Tamar
Te Raa, Doreen
Tonino, Sanne H.
Trentin,
Livio
Van der Spek, Ellen
van Gelder, Michel
van Kampen,
Roel
Varettoni, Marzia
Visentin, Andrea
Vitale, Candida and
Wasik-Szczepanek, Ewa
Wrobel, Tomasz
Yanez San Segundo, Lucrecia
and Yassin, Mohamed
Coscia, Marta
Rambaldi, Alessandro and
Montserrat, Emili
Foa, Robin
Cuneo, Antonio
Stamatopoulos,
Kostas
Ghia, Paolo

Leukemia Research

SPRINGERNATURE

35

12

3444-3454

https://doi.org/10.1038/s41375-021-01450-8

10.1038/s41375-021-01450-8

https://pergamos.lib.uoa.gr/uoa/dl/object/3032545